Cargando…
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
BACKGROUND: Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by hamartomatous growths in the brain, skin, kidneys, lungs, and heart, which lead to significant morbidity. TSC is caused by mutations in the TSC1 or TSC2 genes, whose products, hamartin a...
Autores principales: | Lee, Nancy, Woodrum, Chelsey L, Nobil, Alison M, Rauktys, Aubrey E, Messina, Michael P, Dabora, Sandra L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670829/ https://www.ncbi.nlm.nih.gov/pubmed/19368729 http://dx.doi.org/10.1186/1471-2210-9-8 |
Ejemplares similares
-
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007) -
Comparison of three rapamycin dosing schedules in A/J Tsc2(+/- )mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors
por: Woodrum, Chelsey, et al.
Publicado: (2010) -
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008) -
Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011) -
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)